Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Announcement & Circular
Stock Information
02186.HK
1.78 0.01  (0.56%)
TradingVolume：6469
04-07
2025
VOLUNTARY ANNOUNCEMENT CLASS 1 INNOVATIVE ANTIDEPRESSANT RUOXINLIN APPROVED FOR MARKETING IN MACAO
Publisher：
04-02
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Publisher：
03-31
2025
VOLUNTARY ANNOUNCEMENT RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN JAPAN
Publisher：
03-30
2025
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
Publisher：
03-14
2025
NOTICE OF BOARD MEETING
Publisher：
03-10
2025
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Publisher：
03-10
2025
CHANGE OF NON-EXECUTIVE DIRECTOR
Publisher：
03-05
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Publisher：
02-05
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Publisher：
01-15
2025
FIRST PATIENT ENROLLED FOR THE PHASE 2 CLINICAL STUDY OF THE GROUP'S NEW DRUG LY03015 IN CHINA
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Stock Information
02186.HK
TradingVolume：6469
1.78
0.01  (0.56%)
Announcement & Circular
04-07
2025
VOLUNTARY ANNOUNCEMENT CLASS 1 INNOVATIVE ANTIDEPRESSANT RUOXINLIN APPROVED FOR MARKETING IN MACAO
04-02
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
03-31
2025
VOLUNTARY ANNOUNCEMENT RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN JAPAN
03-30
2025
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
03-14
2025
NOTICE OF BOARD MEETING
03-10
2025
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
03-10
2025
CHANGE OF NON-EXECUTIVE DIRECTOR
03-05
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
02-05
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
01-15
2025
FIRST PATIENT ENROLLED FOR THE PHASE 2 CLINICAL STUDY OF THE GROUP'S NEW DRUG LY03015 IN CHINA
First
1
2
3
4
5
Last